Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults;Clofarabina en el Tratamiento de Leucemia Mieloide Aguda de Nuevo Diagnóstico en Adultos Mayores

Annals of Pharmacotherapy

Volumn 46, Issue 1, 2012, Pages 89-96

  Tran, Huyentran ^a   Yang, Daisy ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Clofarabine

Indexed keywords

CLOFARABINE; CYTARABINE; DAUNORUBICIN; IDARUBICIN; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CAPILLARY LEAK SYNDROME; CYTOPENIA; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FLUSHING; HAND FOOT SYNDROME; HEADACHE; HUMAN; INFLAMMATION; KIDNEY DISEASE; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; REVIEW; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENINE NUCLEOTIDES; AGED; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84855686841     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q295     Document Type: Review

References (31)

1. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin Proc 2006;81:247-60.
2. Surveillance Epidemiology and End Results (SEER). Acute myeloid leukemia. www.seer.cancer.gov/statfacts/html/amyl.html (accessed 2011 Jul 1).
3. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62.
4. Baer MR, Gojo I. Novel agents for the treatment of acute myeloid leukemia in the older patient. J Natl Compr Canc Netw 2011;9:331-5.
5. Acute myeloid leukemia. NCCN Clinical Practice Guidelines in Oncology (Version 2.2011). 2010. National Comprehensive Cancer Network, Inc. http://www.nccn.org (accessed 2011 Jul 1).
6. Product information. Clolar (clofarabine). Cambridge, MA: Genzyme Corporation, May 2009.
7. Thomas X, Raffoux E, Elhamri M, Lobe I, Cannas G, Dombret H. Clofarabine for the treatment of adult acute myeloid leukemia. Future Oncol 2009;5:1197-210.
8. Craig CM, Schiller GJ. Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. Blood Rev 2008;22:221-34.
9. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-5.
10. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006;108:63-73.
11. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
12. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-9.
13. Fröhling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006;108:3280-8.
14. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090-8.
15. Malfuson JV, Etienne A, Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 2008;93:1806-13.
16. Etienne A, Esterni B, Charbonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007;109:1376-83.
17. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88:2841-51.
18. Kantarjian H, Ravandi F, O'Brien S. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010;116:4422-9.
19. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
20. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549-55.
21. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-85.
22. Zhenchuk A, Lotfi K, Juliusson G, Albertioni F. Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol 2009;78:1351-9.
23. Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W, Kantarjian H. Clofarabine in leukemia. Expert Rev Hematol 2010;3:15-22.
24. Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Canc Res 2003;9:6335-42.
25. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010;28:2389-95.
26. Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009;145:598-605.
27. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114-24.
28. Burnett AK, Milligan D, Goldstone A, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009;145:318-32.
29. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006;108:45-51.
30. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low dose cytarabine as front-line therapy for patients age 60 years or older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638-45.
31. Red Book Online (intranet database). Ann Arbor, MI: Thomson Reuters Healthcare. (accessed 2011 Jul 1).